Emma Houlder
@emmahoulder.bsky.social
Researcher at LUMC.
Immunology, schistosomiasis, vaccines.
Immunology, schistosomiasis, vaccines.
Thanks of course to all my co-authors (Uganda, Netherlands and UK) and funders!!!!!!!
July 31, 2025 at 3:15 PM
Thanks of course to all my co-authors (Uganda, Netherlands and UK) and funders!!!!!!!
[6/7]
Thanks to co-authors Lucas Ferreira da Silva, Angela van Diepen, Murilo Sena Amaral, R. Alan Wilson, Cornelis Hokke, Meta Roestenberg & Wilfried Bakker, and to the wider #WORMVACS group.
Thanks to co-authors Lucas Ferreira da Silva, Angela van Diepen, Murilo Sena Amaral, R. Alan Wilson, Cornelis Hokke, Meta Roestenberg & Wilfried Bakker, and to the wider #WORMVACS group.
June 12, 2025 at 2:43 PM
[6/7]
Thanks to co-authors Lucas Ferreira da Silva, Angela van Diepen, Murilo Sena Amaral, R. Alan Wilson, Cornelis Hokke, Meta Roestenberg & Wilfried Bakker, and to the wider #WORMVACS group.
Thanks to co-authors Lucas Ferreira da Silva, Angela van Diepen, Murilo Sena Amaral, R. Alan Wilson, Cornelis Hokke, Meta Roestenberg & Wilfried Bakker, and to the wider #WORMVACS group.
5/7]
We also built an open, searchable database with all results:
🧪 wormvaccines.nl
The idea is to keep it updated with new studies and make the field easier to navigate for anyone working on schisto vaccines.
We also built an open, searchable database with all results:
🧪 wormvaccines.nl
The idea is to keep it updated with new studies and make the field easier to navigate for anyone working on schisto vaccines.
Pre-clinical S.mansoni vaccine dashboard
wormvaccines.nl
June 12, 2025 at 2:43 PM
5/7]
We also built an open, searchable database with all results:
🧪 wormvaccines.nl
The idea is to keep it updated with new studies and make the field easier to navigate for anyone working on schisto vaccines.
We also built an open, searchable database with all results:
🧪 wormvaccines.nl
The idea is to keep it updated with new studies and make the field easier to navigate for anyone working on schisto vaccines.
[4/7]
To address that, we pulled out common parameters that influence outcomes and proposed recommendations for future pre-clinical study design.
To address that, we pulled out common parameters that influence outcomes and proposed recommendations for future pre-clinical study design.
June 12, 2025 at 2:43 PM
[4/7]
To address that, we pulled out common parameters that influence outcomes and proposed recommendations for future pre-clinical study design.
To address that, we pulled out common parameters that influence outcomes and proposed recommendations for future pre-clinical study design.
[3/7]
One major issue: huge variation in vaccine formulation and study design.
Different adjuvants, challenge doses, timing, and endpoints make it hard to compare studies—or know whether a low result is due to the antigen or the setup.
One major issue: huge variation in vaccine formulation and study design.
Different adjuvants, challenge doses, timing, and endpoints make it hard to compare studies—or know whether a low result is due to the antigen or the setup.
June 12, 2025 at 2:42 PM
[3/7]
One major issue: huge variation in vaccine formulation and study design.
Different adjuvants, challenge doses, timing, and endpoints make it hard to compare studies—or know whether a low result is due to the antigen or the setup.
One major issue: huge variation in vaccine formulation and study design.
Different adjuvants, challenge doses, timing, and endpoints make it hard to compare studies—or know whether a low result is due to the antigen or the setup.
[2/7]
A few candidates—like Smp-80 and Cathepsin B—stood out, with >90% protection in some studies.
But the median efficacy across all candidates was around 35%.
A few candidates—like Smp-80 and Cathepsin B—stood out, with >90% protection in some studies.
But the median efficacy across all candidates was around 35%.
June 12, 2025 at 2:42 PM
[2/7]
A few candidates—like Smp-80 and Cathepsin B—stood out, with >90% protection in some studies.
But the median efficacy across all candidates was around 35%.
A few candidates—like Smp-80 and Cathepsin B—stood out, with >90% protection in some studies.
But the median efficacy across all candidates was around 35%.
Huge thanks to all! @emerhickey.bsky.social @profandrewmac.bsky.social @darrenthomson.bsky.social @billhorsnell.bsky.social and all others without bluesky!!!!
December 20, 2024 at 10:40 AM
Huge thanks to all! @emerhickey.bsky.social @profandrewmac.bsky.social @darrenthomson.bsky.social @billhorsnell.bsky.social and all others without bluesky!!!!